Background: Patient-reported outcome measures (PROM) have been shown to have important prognostic value after various cardiac interventions. We assessed the association between the change in Kansas City Cardiomyopathy Questionnaire 12 (KCCQ-12) score after transcatheter aortic valve replacement (TAVR) and mortality. Methods: We included patients who underwent TAVR at Mayo Clinic between February 2012, and June 2022, who completed KCCQ-12 prior to and 30-45 days after the procedure. Patients were categorized into 3 groups: those who experienced significant (≥19 points; group-1), modest (1-19 points; group-2), and no improvement (≤0 points; group-3). Results: A total of 1,124 patients were included: 60.8% males; 97.6% Caucasian. Mean age was 79.4±8.3 years, KCCQ-12 score was 53.9±24.5, and median STS score was 4.9% (interquartile range 3.1-8.0). At 45 days, the mean change in KCCQ-12 score was 19±24 points: 46.3% (n= 520) of patients had a significant improvement in their KCCQ-12 score, while 33.4% (n= 375) and 20.4% (n = 229) had modest and no improvement, respectively. Median survival was higher in group-1 (5.7±0.2 years) compared to groups 2 and 3 (5.1±0.3 and 4.1±0.4 years, respectively; P<.001). Compared to patients in group 1, those in groups 2 and 3 had higher long-term risk-adjusted mortality (adjusted hazard ratio 1.64; 95%CI 1.28-2.10, and 2.44; 95%CI, 1.84-3.24, respectively). Conclusion: Patients who experience modest or no improvement in KCCQ-12 score after TAVR have substantially higher long-term mortality. Delta KCCQ-12 is a cost-effective, efficient tool that can identify patients at increased risk of death at long-term follow-up post-TAVR.

The authors have declared no competing interest.

None.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Mayo Clinic - Rochester's IRB.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

De-identified data can be shared by the corresponding author upon request.